Clinical Pharmacokinetics

, Volume 41, Issue 1, pp 19–30

Clinical Pharmacokinetics of Salmeterol

  • Mario Cazzola
  • Renato Testi
  • Maria Gabriella Matera
Review Article Drug Disposition


Salmeterol is an inhaled long-acting selective β2-adrenoceptor agonist that is commercially available as the xinafoate (1-hydroxy-2-naphthoic acid) salt of the racemic mixture of the two optical isomers, (R)- and (S)-, of salmeterol. It acts locally in the lung through action on β2 receptors.

Limited data have been published on the pharmacokinetics of salmeterol. Moreover, there are no data on the extent to which inhaled salmeterol undergoes first-pass metabolism. This lack of information is most likely due to the very low plasma concentrations reached after inhalation of therapeutic doses of salmeterol and the problems in developing an analytical method that is sensitive enough to determine these concentrations.

When salmeterol is inhaled, plasma concentrations of the drug often cannot be detected, even at 30 minutes after administration of therapeutic doses. Larger inhaled doses give approximately proportionally increased blood concentrations. Plasma salmeterol concentrations of 0.1 to 0.2 and 1 to 2 µg/L have been attained in healthy volunteers about 5 to 15 minutes after inhalation of a single dose of 50 and 400 µg, respectively. In patients who inhaled salmeterol 50µg twice daily for 10 months, a second peak concentration of 0.07 to 0.2 µg/L occurred 45 to 90 minutes after inhalation, probably because of the gastrointestinal absorption of the swallowed drug.

Salmeterol xinafoate dissociates in solution to salmeterol and 1-hydroxy-2-naphthoic acid. These two compounds are then absorbed, distributed, metabolised and excreted independently. The xinafoate moiety has no apparent pharmacological activity, is highly protein bound (>99%), largely to albumin, and has a long elimination half-life of about 12 to 15 days in healthy individuals. For this reason, it accumulates in plasma during repeated administration, with steady-state concentrations reaching about 80 to 90 µg/L in patients treated with salmeterol 50µg twice daily for several months.

The cytochrome P450 (CYP) isoform 3A4 is responsible for aliphatic oxidation of salmeterol base, which is extensively metabolised by hydroxylation with the major metabolite being α-hydroxysalmeterol, with subsequent elimination predominantly in the faeces. It has been demonstrated that 57.4% of administered radioactivity is recovered in the faeces and 23% in the urine; most is recovered between 24 and 72 hours after administration. Unchanged salmeterol accounts for <5% of the excreted dose in the urine.

Since the therapeutic dose of salmeterol is very low, it is unlikely that any clinically relevant interactions will be observed as a consequence of the coadministration of salmeterol and other drugs, such as fluticasone Propionate, that are metabolised by CYP3A.

All the available data clearly show that at the recommended doses of salmeterol, systemic concentrations are low or even undetectable. This is an important point, because it has been demonstrated that the systemic effects of salmeterol are more likely to occur with higher doses, which lead to approximately proportionally increased blood concentrations.


  1. 1.
    Taburet A-M, Schmit B. Pharmacokinetic optimisation of asthma treatment. Clin Pharmacokinet 1994; 26: 396–418PubMedCrossRefGoogle Scholar
  2. 2.
    Jenne JW. Pharmacodynamics and clinical management. In: Leff AR, editor. Pulmonary and critical care pharmacology and therapeutics. New York: McGraw-Hill, 1996: 489–495Google Scholar
  3. 3.
    Lima JJ, Thomason DB, Mohamed MH, et al. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999; 65: 519–25PubMedCrossRefGoogle Scholar
  4. 4.
    Hochhaus G, Schmidt E, Rominger KL, et al. Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. Pharm Res 1992; 9: 291–7PubMedCrossRefGoogle Scholar
  5. 5.
    Morgan DJ. Clinical pharmacokinetics of β-agonists. Clin Pharmacokinet 1990; 18: 270–94PubMedCrossRefGoogle Scholar
  6. 6.
    Kerrebijn KF. Long-term drug treatment of asthma in children. Lung 1990; 168 Suppl: 142–53PubMedCrossRefGoogle Scholar
  7. 7.
    Newman SP. Therapeutic aerosols. In: Clarke SW, Pavia D, editors. Aerosols and the lung. London: Butterworths, 1984: 197–224Google Scholar
  8. 8.
    Clark DJ, Lipworth BJ. Dose-response of inhaled drugs in asthma. An update. Clin Pharmacokinet 1997; 32: 58–74PubMedCrossRefGoogle Scholar
  9. 9.
    Rodrigo G, Rodrigo C. Metered dose inhaler salbutamol treatment of asthma in the ED: comparison of two doses with plasma levels. Am J Emerg Med 1996; 14: 144–50PubMedCrossRefGoogle Scholar
  10. 10.
    Johnson M, Butchers PR, Coleman RA, et al. The pharmacology of salmeterol. Life Sci 1993; 52: 2131–47PubMedCrossRefGoogle Scholar
  11. 11.
    Ball DI, Brittain RT, Coleman RA, et al. Salmeterol, a novel, long-acting β2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 1991; 104: 665–71PubMedCrossRefGoogle Scholar
  12. 12.
    Linden A, Rabe KF, Löfdahl CG. Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting β2-adrenoceptor agonists. Lung 1996; 174: 1–22PubMedGoogle Scholar
  13. 13.
    Rhodes DG, Newton R, Butler R, et al. Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers. Mol Pharmacol 1992; 42: 596–602PubMedGoogle Scholar
  14. 14.
    Anderson GP, Linden A, Rabe KF. Why are long-acting betaadrenoceptor agonists long-acting? Eur Respir J 1994; 7: 569–78PubMedCrossRefGoogle Scholar
  15. 15.
    Isogaya M, Yamagiwa Y, Fujita S, et al. Identification of a key amino acid of the β2-adrenergic receptor for high affinity binding of salmeterol. Mol Pharmacol 1998; 54: 616–22PubMedGoogle Scholar
  16. 16.
    Green SA, Spasoff AP, Coleman RA, et al. Sustained activation of a G protein-coupled receptor via ‘anchored’ agonist binding. Molecular localization of the salmeterol exosite within the β2-adrenergic receptor. J Biol Chem 1996; 271: 24029–35PubMedCrossRefGoogle Scholar
  17. 17.
    Teschemacher A, Lemoine H. Kinetic analysis of drug-receptor interactions of long-acting β2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. J Pharmacol Exp Ther 1999; 288: 1084–92PubMedGoogle Scholar
  18. 18.
    Källström BL, Sjoberg J, Waldeck B. The interaction between salmeterol and β2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol 1994; 113: 687–92PubMedCrossRefGoogle Scholar
  19. 19.
    Jack D. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other β-adrenoceptor agonists. Br J Clin Pharmacol 1991; 31: 501–14PubMedCrossRefGoogle Scholar
  20. 20.
    Johnson M. The β-adrenoceptor. Am J Respir Crit Care Med 1998; 158(5 Pt 3): S146–53PubMedGoogle Scholar
  21. 21.
    Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405–11PubMedCrossRefGoogle Scholar
  22. 22.
    Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol in asthmatic patients: an evaluation of asthma symptoms and the possible development of tachyphlyaxis. Am Rev Respir Dis 1990; 142: 571–5PubMedCrossRefGoogle Scholar
  23. 23.
    Wang S, Collins S. Regulation of the β2-adrenergic receptor by the long-acting agonist salmeterol in human bronchial epithelial cells [abstract]. Am J Respir Crit Care Med 1996; 153: A730Google Scholar
  24. 24.
    Anderson P, Lötvall J, Linden A. Relaxation kinetics of formoterol and salmeterol in the guinea pig trachea in vitro. Lung 1996; 174: 159–70PubMedGoogle Scholar
  25. 25.
    Linden A, Bergendal A, Ullman A, et al. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax 1993; 48: 547–53PubMedCrossRefGoogle Scholar
  26. 26.
    Coleman RA, Johnson M, Niais AT, et al. Exosites: their current status, and their relevance to the duration of action of longacting β2-adrenoceptor agonises. Trends Pharmacol Sci 1996; 17: 324–30PubMedCrossRefGoogle Scholar
  27. 27.
    Jeppsson AB, Roos C, Waldeck B, et al. Pharmacodynamic and pharmacokinetic aspects on the transport of bronchodilator drugs through the tracheal epithelium of the guinea-pig. Pharmacol Toxicol 1989; 64: 58–63PubMedCrossRefGoogle Scholar
  28. 28.
    Bennett JA, Tattersfield AE. Time course and relative dose potency of systemic effects from salbutamol and salmeterol in healthy subjects. Thorax 1997; 52: 458–64PubMedCrossRefGoogle Scholar
  29. 29.
    Maconochie JG. Forster JK. Dose-response study with high-dose inhaled salmeterol in healthy subjects. Br J Clin Pharmacol 1992; 33: 342–5PubMedCrossRefGoogle Scholar
  30. 30.
    Committee on Drugs, American Academy of Allergy, Asthma and Immunology. Safety and appropriate use of salmeterol in the treatment of asthma. J Allergy Clin Immunol 1996; 98: 475–80CrossRefGoogle Scholar
  31. 31.
    Prevost A, Leperre A, Moreau F, et al. Cardiotoxic effects of salmeterol in comparison with salbutamol on the isolated perfused Langendorff-heart of the rat. Arzneimittel Forschung 1997; 47: 39–43PubMedGoogle Scholar
  32. 32.
    Bennett JA, Harrison TW, Tattersfield AE. The contribution of the swallowed fractions of an inhaled dose of salmeterol to its systemic effects. Eur Respir J 1999; 13: 445–8PubMedCrossRefGoogle Scholar
  33. 33.
    Ward JK, Man CY, Horton J, et al. Systemic dynamic responses to oral doses of salmeterol in healthy subjects — effect of activated charcoal [abstract]. Am J Respir Crit Care Med 1997; 155: A346Google Scholar
  34. 34.
    Adkins JC, McTavish D. Salmeterol. Areview of its pharmacological properties and clinical efficacy in the management of children with asthma. Drugs 1997; 54: 331–54PubMedCrossRefGoogle Scholar
  35. 35.
    Higton D, Clegg C, Oxford J. GC-MS determination of salmeterol in human plasma following inhaled administration. In: Reid E, Wilson ID, editors. Methodological surveys in biochemistry and analysis. London: Royal Society of Chemistry, 1992; 22: 235–8Google Scholar
  36. 36.
    Colthup PV, Young GC, Feigate CC. Determination of salmeterol in rat and dog plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Sci 1993; 82: 323–5PubMedCrossRefGoogle Scholar
  37. 37.
    Chilton AS, Godward RE, Carey PF. The determination in human plasma of l-hydroxy-2-naphthoic acid following administration of salmeterol xinafoate. J Pharm Biomed Anal 1995; 13: 165–9PubMedCrossRefGoogle Scholar
  38. 38.
    Jones AE, Callejas S, Sadra P, et al. The determination of drugs for the treatment of asthma in plasma by automated solid phase extraction and LC-MS-MS [abstract]. Proceedings of the 45th The American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics; 1997; Palm Springs. 560Google Scholar
  39. 39.
    Kim KH, Yun HW, Kim HJ, et al. Coupled column chromatography in chiral separation of salmeterol. Arch Pharm Res 1998; 21: 212–6PubMedCrossRefGoogle Scholar
  40. 40.
    Zhang M, Fawcett JP, Shaw JP. Rapid chiral high-performance liquid Chromatographic assay for salmeterol and α-hydroxysalmeterol. Application to in vitro metabolism studies. J Chromatogr B Biomed Sci Appl 1999; 729: 225–30PubMedCrossRefGoogle Scholar
  41. 41.
    Manchee GR, Barrow A, Kulkarni S, et al. Disposition of salmeterol xinafoate in laboratory animals and humans. Drug Metab Dispos 1993; 21: 1022–8PubMedGoogle Scholar
  42. 42.
    Bowers GD. Bayliss MK. Donnelly MC., et al. The characterisation of the major metabolites of salmeterol in the dog. J Pharm Biomed Anal 1998; 18: 461–70PubMedCrossRefGoogle Scholar
  43. 43.
    Brogden RN, Faulds D. Salmeterol xinafoate. Areview of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991; 42: 895–912PubMedCrossRefGoogle Scholar
  44. 44.
    Barnhart ER. Salmeterol xinafoate. Physicians’ desk reference. Oradell (NJ): Medical Economics Company, 1998: 108–111Google Scholar
  45. 45.
    Glaxo Wellcome. (Data on file)Google Scholar
  46. 46.
    Wolfe J, Kreitzer S, Chervinsky P, et al. Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma. Ann Allergy Asthma Immunol 2000; 84: 334–40PubMedCrossRefGoogle Scholar
  47. 47.
    Manchee GR, Eddershaw PJ, Ranshaw LE, et al. The aliphatic oxidation of salmeterol to α-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A. Drug Metab Dispos 1996; 24: 555–9PubMedGoogle Scholar
  48. 48.
    Kirby S, Falcoz C, Daniel MJ, et al. Salmeterol and fluticasone Propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol 2001; 56: 781–91PubMedCrossRefGoogle Scholar
  49. 49.
    Buchwald A, Hochhaus G. Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy. Intern J Clin Pharmacol Ther 1998; 36: 652–60Google Scholar
  50. 50.
    Vaisman N, Koren G, Goldstein D, et al. Pharmacokinetics of inhaled salbutamol in patients with cystic fibrosis versus healthy young adults. J Pediatr 1987; 111: 914–7PubMedCrossRefGoogle Scholar
  51. 51.
    Schmekel B, Borgstrom L, Wollmer P. Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and nonsmokers. Thorax 1991; 46: 225–8PubMedCrossRefGoogle Scholar
  52. 52.
    Newman SP. Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs? Br J Clin Pharmacol 2000; 49: 529–37PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Mario Cazzola
    • 1
  • Renato Testi
    • 1
  • Maria Gabriella Matera
    • 2
  1. 1.Department of Respiratory MedicineA. Cardarelli HospitalNapoliItaly
  2. 2.Department of Experimental MedicineSecond University of NaplesNaplesItaly

Personalised recommendations